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To determine the relationship between serum concentrations of uric acid and insulin secretion with hyperglycaemic clamp
technique among adults with type 2 diabetes mellitus (DM2) without hyperuricemia, we carried out a cross-sectional study on
45 patients of both gender. We observed correlation between uric acid with male gender r = 0.710 (P = 0.001). Also correlation
between uric acid and total insulin secretion was positive r = 0.295 (P = 0.049). As well as a positive correlation adjusted for body
mass index was demonstrated for the ﬁrst, second, and total phases of insulin secretion, respectively, r = 0.438 (P = 0.022), r =
0.433 (P = 0.022), and r = 0.439 (P = 0.024). Serum concentration of uric acid showed a positive relationship with the total phase
of insulin secretion; even in states prior to hyperuricemia, uric acid can play an important role in the function of the beta cell in
patients with DM2.
1.Introduction
Hyperuricemia is a condition that is signiﬁcantly associated
with markers of metabolic syndrome such as dyslipidemia,
glucose intolerance, high blood pressure, and central obesity,
which are accepted as risk factors for developing cardio-
vascular disease. Hyperuricemia is probably associated with
glucose intolerance due to various mechanisms; however, the
most important is the association between insulin and renal
resistance to absorption of urates [1].
Hyperuricemia has been associated with insulin resis-
tance; however, there are few studies where the association
of hyperuricemia-insulin resistance and beta cell function
is evaluated. A modest positive association between con-
centrations of uric acid and incidence in type 2 diabetes
mellitus was observed in a cohort of a Chinese population
[2]. It was reported recently in another cohort that uric
acid is a risk factor for development of DM2 [3]. At the
same time, another study demonstrated that serum uric acid
values may be useful as predictors of DM2 in adults who
are glucose intolerant [4]. Cohort studies support the fact
that uric acid is a risk factor for developing DM2; in a meta-
analysis by Kodama et al. [5], the authors concluded that the
variabilityoftheresultsandcontrolofconfoundingvariables
should be considered in the ﬁnal analysis of competitive
models for interpreting the results regarding the role of uric
acid as a risk factor for developing DM2. In a study that
reported beta cell function with HOMA in subjects with
hyperuricemia, failure of beta cells to compensate for the
variation in insulin sensitivity was demonstrated [6]. These
studies from diﬀerent population samples established an
association between serum uric acid and prevalence of DM2,
however a temporal eﬀect between uric acid and diﬀerent
phases of insulin secretion cannot be shown by these data.
The role of uric acid as a continuous variable and its
relationship to insulin secretion without hyperuricemia in
patientswithDM2inamodelsuchastheclamphasnotbeen
evaluated.
The aim of this study was to determine the relationship
between serum concentrations of uric acid with insulin2 International Journal of Endocrinology
secretion in adults with DM2 without hyperuricemia using
the hyperglycaemic clamp technique.
2.MaterialandMethods
A cross-sectional analytical study was carried out in 45
subjects of both genders. Subjects were between 40 and 60
years of age and were classiﬁed as overweight or grade I
obesity and diagnosis of DM2 <5 years of evolution accord-
ing to the American Diabetes Association (ADA) criteria.
All individuals were nonsmokers. Their body weight was
stable for at least 3 months before the study. Blood pressure
was less than 130/80mmHg. Subjects denied use of any
medications known to aﬀect metabolism.
At the time of the study, patients were not taking hypo-
glycemic agents approved for glucose control or they were
unaware as to the eﬀects of uric acid. The study protocol was
reviewed and approved by the hospital-based ethics commit-
tee, and written informed consent was obtained from all vol-
unteers. Subjects were selected from metropolitan Guadala-
jara, Jalisco, Mexico living in the same residential area
and of similar socioeconomic status.
The study was performed at 8:00AM after a 10–12 hour
overnightfast.Forallparticipants,aclinicalhistorywasdone
using the following determinations (weight, height, body
massindex(BMI),waistcircumference(WC),hipcircumfer-
ence(HC),waist/hipratio(WHR),andbloodpressure(BP))
followed by laboratory tests to determine glucose, HbA1c,
creatinine, uric acid, total cholesterol (TC), triglycerides
(TG), very-low-density lipoprotein cholesterol (VLDL-C),
high-density lipoprotein cholesterol (HDL-C), low-density
lipoprotein cholesterol (LDL-C), and serum insulin con-
centrations. We ﬁnally determined the phases of insulin
secretion using hyperglycaemic clamp technique.
Serum glucose was determined using the glucose-oxidase
technique (Boehringer Mannheim GmbH, Mannheim, Ger-
many), with an intra- and interassay coeﬃcient of variation
<3%. For determination of HbA1c levels, ion-exchange
high-performance liquid chromatography was carried out
(Bio-Rad Laboratories, Hercules, Calif) with an intra-assay
coeﬃcient of variation of 2.8% and 3.5% and intera-ssay
coeﬃcient of variation <3.0%. Creatinine, uric acid, and
lipid proﬁle (TC, HDL-C, TG, LDL-C, and VLD-CL) were
measured enzymatically (Ortho-Clinical Diagnostics, John-
son&JohnsonCompany,Rochester,NY,USA)withanintra-
and interassay coeﬃcient of variation <2%. Insulin concen-
trations were measured using the microparticle enzymatic
immunoassay method (Abbott Diagnostics Division, Japan
Co.Ltd.)withanintra-andinterassaycoeﬃcientofvariation
of 3.3 and 3.8%, respectively.
To determine the phases of insulin secretion, hyper-
glycemic clamp technique was performed. Brieﬂy, two
venous accesses were installed: the ﬁrst was retrograde over
hand veins through a 19-gauge butterﬂy catheter used for
sample taking during the test. The hand was wrapped in
a thermal pillow to achieve a local temperature of 40◦C
in order to arterialize the blood. The second access was
installed on the contralateral arm with a 19-gauge catheter.
A 20% dextrose infusion was initiated: a priming dose for
14min equivalent to 240mg/kg body weight followed by a
maintenance dose based on body weight, basal glucose, and
the glucose required throughout the test (6.9mmol/L above
basalvalue).At2,4,6,8,and10min,5mLofbloodwastaken
and, after that, each 10min for 120min for insulin deter-
mination. At 5min intervals, an additional 1.5mL blood
sample was taken for glucose determination to calculate
the estimate of glucose metabolism as well as to adjust
the rate of dextrose infusion. At the end of the test (120min),
dextrose infusion was maintained for 30min as a precaution
to avoid hypoglycemia. With the above-mentioned results
and using a calculator program, ﬁrst (0–10min) and late
(10–120min) phases of insulin secretion as well as total
insulin concentration (0–120min) were calculated. Area
underthecurvewasdeterminedusingintegrationofpolyno-
mials for glucose regressions and phases of insulin secretion
2.1. Statistical Analysis. Results were converted to the Inter-
national System of Units and presented as mean ± standard
deviation (SD). Pearson bivariate correlations between uric
acid and clinical and laboratory variables to establish a
relationship with the gender Spearman correlation were
performed. The relationship of uric acid with insulin secre-
tion and other adjusted variables was determined with the
Pearson correlation test. Statistical analyses were performed
using STATA/SE v.8.0 for Windows.
3. Results
Forty-ﬁve patients were recruited into the study (Table 1).
There were 21 (46.6%) males and 24 (53.4%) females. There
was no statistical signiﬁcance in age according to gender
(48 ± 4v e r s u s4 8± 5y e a r s ,P = 0.850) or in BMI (29.8 ±
2.7 versus 30.6 ± 3.0kg/m2, P = 0.419) between males and
females, respectively.
M a l e sh a dal a r g e rW Ca sw e l la sh i g h e rB P .Ap o s i t i v e
relationship was observed for male gender, BMI, WC,
and fasting insulin according to the bivariate correlation
(Table 2).
We observed a positive correlation between uric acid and
total insulin secretion r = 0.295 (P = 0.049) (Table 3). Also
a positive correlation adjusted for BMI was demonstrated for
the ﬁrst and second phases, respectively, r = 0.438 (P =
0.022), r = 0.433 (P = 0.022) as well as in total insulin
secretion r = 0.439 (P = 0.024) (Table 4); variables that were
found signiﬁcant in the bivariate model with uric acid were
not signiﬁcant in correlation with the phases of secretion.
4. Discussion
The association of hyperuricemia and development of DM2
have been observed by various investigators. However, there
are no previous studies showing the possible relationship of
serum uric acid with diﬀerent phases of insulin secretion
using a hyperglycemic-hyperinsulinemic clamp technique in
subjects with DM2 without hyperuricemia. The mechanisms
b yw h i c hu r i ca c i di si n v o l v e di nb e t ac e l lf u n c t i o no rg l u c o s eInternational Journal of Endocrinology 3
Table 1: Clinical and biochemical characteristics in study.
Variables Total
n = 45
Age, years 48.7 ± 4.9
Body mass index, kg/m2
Male 29.8 ± 2.7
Female 30.6 ± 3.0
Waist circumference, cm
Male 106.0 ± 11.4
Female 97.7 ± 8.6
Systolic blood pressure, mmHg 117.1 ± 9.4
Diastolic blood pressure, mmHg 76.7 ± 6.9
Glucose, mg/dL 138.7 ± 29.0
HbA1c, % 7.7 ± 1.0
Uric acid, mg/dL 5.2 ± 1.0
Cholesterol, mg/dL 181.9 ± 30.4
Triglycerides, mg/dL 182.4 ± 68.5
LDL-C, mg/dL 106.1 ± 25.6
HDL-C, mg/dL 37.3 ± 10.5
Insulin, μU/mL 14.7 ± 7.2
Glucose metabolized∗, mg/kg/min 3.6 ± 0.7
Phase 1 of Insulin secretion, μU/mL 18.2 ± 11.5
Phase 2 of Insulin secretion, μU/mL 37.5 ± 21.3
Insulin secretion total, μU/mL 29.8 ± 16.4
LDL-C: low-density lipoprotein cholesterol; HDL-C: high-density lipopro-
tein cholesterol.






Male∗ 0.710 0.001 0.000–0.025
BMI, kg/m2 0.381 0.009 0.087–0.603
WC, cm 0.468 0.001 0.038–0143
SBP, mmHg −0.127 0.408 −0.364–0.151
DBP, mmHg −0.057 0.708 −0.920–0.631
Glucose, mg/dL −0.013 0.931 −0.836–0.767
HbA1c, % 0.078 0.607 −2.666–4508
Cholesterol, mg/dL 0.106 0.484 −0.061–0.126
TG, mg/dL 0.247 0.101 −0.002–0.032
LDL-C, mg/dL 0.053 0.727 −0.184–0.263
HDL-C, mg/dL −0.185 0.222 −0.248–0.059
Insulin, μU/mL 0.331 0.026 0.017–0.259
M, mg/kg/min −0.192 0.204 −3.296–0.725
BMI: body mass index; WC: waist circumference; SBP: systolic blood pres-
sure; DBP: diastolic blood pressure; TG: triglycerides; LDL-C: low-density
lipoprotein cholesterol; HDL-C: high-density lipoprotein cholesterol; M:
glucose metabolized (calculated with the clamp technique).
∗Spearman correlation.
concentrationsandeventhedevelopmentofDM2inthelong
term are uncertain. It is accepted that the most important
Table 3:Correlationbetweenuricacidandinsulinsecretionphases.
Uric acid
r P 95% CI
Phase 1 of ScI, μU/mL 0.291 0.052 −0.000–0.175
Phase 2 of ScI, μU/mL 0.279 0.063 −0.002–0.097
ScI total, μU/mL 0.295 0.049 0.037–0.122
95% CI: 95% conﬁdence interval; ScI: insulin secretion.
Table 4: Correlation between uric acid and insulin secretion phases
adjusted by body mass index.
Uric acid
r P 95% CI
Phase 1 of ScI, μU/mL 0.438 0.022 0.039–0.488
Phase 2 of ScI, μU/mL 0.433 0.022 0.041–0.498
ScI total, μU/mL 0.439 0.024 0.036–0.486
95% CI: 95% conﬁdence interval; ScI: insulin secretion.
mechanism may be that of the association of insulin resis-
tance on renal absorption of urates [1]. Likewise, inhibition
of uricase in a rat model revealed a decrease in serum insulin
and hyperglycemia and rapid removal of basal insulin in in
vitro secretion as well as reversing the eﬀect of the removal
of uric acid, suggesting an interference with the mechanism
of insulin secretion [7]. Another study reported evidence of
the involvement and role of uric acid on the alteration of the
primary function of the beta cell and suggests the presence
of an arginine residue combined with a critical site of the
cell. The default is probably due more to an alteration in
the secretion from the stimulus with a secretagogue than to
an adverse eﬀect on the viability of the beta cell [8]. Recent
studies have reported the pro-oxidative capacity of uric acid
in the diﬀerentiation of preadipocytes to adipocytes, an
increase in reactive oxygen species (ROS) by activation of the
NADPH oxidase, and sustained inﬂammation, mechanisms
that may promote insulin resistance and impaired insulin
secretion [9].
Anotherstudyexploredtherelationshipbetweenbetacell
function and uric acid. Insulin secretion was stimulated with
L-arginine, and it was observed that in subjects with hype-
ruricemia and insulin resistance beta cell function increased
from its compensatory state [10]. In a study comparing four
study groups (control, type 2 diabetes: with and without
obesity and type 1 diabetes), C-peptide levels were increased
in patients who had type 2 diabetes and obesity. It appears
that uric acid behavior is closely related with beta cell
function [11]. This apparently was related to the previously
mentioned information concerning residual arginine in the
beta cell as well as reporting on the stimulation of insulin
secretion in pancreatic tissue of rat where it was observed
that uric acid has no inﬂuence on insulin secretion when
stimulated to euglycemic concentrations (100mg/100mL).
However, when insulin secretion was stimulated to hyper-
glycemic concentrations (300mg/100mL), insulin secretion
was increased by the addition of uric acid >100% [12]. In the
present study, hyperglycemic clamp (200mg/100mL) tech-
nique was used to stimulate insulin secretion, and a positive4 International Journal of Endocrinology
relationship was demonstrated between the serum concen-
tration of uric acid and the total phase of insulin secretion.
The ﬁrst phase of secretion was the most important one and
it inﬂuenced in an important wayon the positive correlation;
this was probably caused by a compensatory response of the
beta cell in subjects with DM2 without hyperuricemia.
5. Conclusions
Serum concentration of uric acid showed a positive relation-
ship with the total phase of insulin secretion; even in states
prior to hyperuricemia, uric acid can play an important role
in the function of the beta cell in patients with DM2.
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